Teshima, Takanori http://orcid.org/0000-0002-0941-271X
Onishi, Yasushi
Kato, Koji
Taniguchi, Shuichi
Miyamura, Koichi
Fukushima, Kentaro
Kato, Jun
Ishikawa, Takayuki
Doki, Noriko
Nakamae, Hirohisa
Maeda, Yoshinobu
Inamoto, Yoshihiro
Okada, Masaya
Maki, Akio
Shimada, Fumika
Tajima, Takeshi
Wroclawska, Monika
Zeiser, Robert
Onizuka, Makoto
Funding for this research was provided by:
Novartis
Article History
Received: 17 December 2023
Revised: 28 March 2024
Accepted: 8 April 2024
First Online: 25 May 2024
Declarations
:
: TT received honoraria from Novartis, Abbvie, Astellas, NIPPON SHINYAKU, Kyowa Kirin, Bristol-Myers Squibb, Sumitomo Pharma, Merck Sharp & Dohme, Celgene, Chugai, and Janssen; research funding from Astellas, Chugai, Fuji Pharma, Kyowa Kirin, Nippon Shinyaku, Asahi Kasei Pharma, Eisai, Sumitomo Pharma, ONO, Shionogi, Priothera SA, LUCA science and Otsuka; advisory board fees from Meiji Seika Pharma, Daiichi Sankyo, Asahi Kasei Pharma, Astellas, AstraZeneca, Takeda, Janssen, Toche Diagnostics, Sumitomo Pharma, Celgene, and Sanofi; manuscript preparation support from Novartis. YO received honoraria from Novartis, Pfizer, Janssen, AsahiKasei, Abbvie, Astellas, Amgen, Chugai, Bristol-Myers Squibb, Symbio, MSD, Meiji Seika, Sumitomo Dainippon,Daiichi Sankyo, Nippon Shinyaku, IQVIA and Kyowa Kirin; research funding from Novartis, Pfizer, Janssen, Meiji Seika, Incyte, and Takara Bio. KK received consulting fees from AbbVie, AstraZeneca, Celgene, Chugai, Daiichi Sankyo, Eisai, Janssen, Novartis, and Ono; honoraria from Bristol-Myers Squibb, Celgene, Dainippon-Sumitomo, Janssen, Kyowa-Kirin, MSD, Mundi, Ono, and Takeda; and research funding from AbbVie, Celgene, Chugai, Daiichi Sankyo, Eisai, Janssen, Kyowa Kirin, Novartis, Ono, and Takeda. KT, KM, KK, ST, KF, TI, ND, MO have nothing to disclose. JK received lecture fees from Bristol-Myers Squibb, Novartis, Janssen, Chugai, and Daiichi-Sankyo. HN received payment from Novartis and Chugai. YM received grants or contracts from Asahi Kasei, Eisai, Otsuka, Kyowa Kirin, Taiho, Takeda, Chugai, Japan blood products, Nippon Kayaku, Nippon Shinyaku, Mallinckrodt, and Regimmune; and payment or Honoria from Asahi Kasei, AstraZeneca, Astellas, Amgen, AbbVie, Viatris, Eisai, MSD, Otsuka, ONO, Gilead, Kyorin, Kyowa, Kissei, Konica, Sanofi, Celgene, Bristol-Myers Squibb, Bayer, CSL Behring, Daiichi Sankyo, Sumitomo Dainippon, Takeda, Terumo, Chugai, Nippon Shinyaku, Novartis, Pfizer, Mundipharma, Human Life CORD, Meiji Seika, Janssen and Yakult Honsha. YI received honoria from Astellas Pharma, Chugai Pharmaceutical, Janssen, Kyowa Kirin, Meiji Seika Pharma, Novartis, and Sumitomo Dainippon Pharma. AM, SF and TTajima are employees of Novartis Pharma K.K., Tokyo, Japan. MW is an employee of Novartis Pharma AG, Basel, Switzerland. RZ received consulting fees from Novartis; speaker fees from Incyte, MNK, Sanofi, VectivBio, and Novartis; and participated on Data safety monitoring or advisory board for Novartis and Incyte.